Shoulder Innovations, Inc. · NYSE:SI
Shoulder Innovations — Investor Presentation (August 2026)
27 slides from Shoulder Innovations's investor presentation, August 2026
Slide 1: Investor Presentation
Investor Presentation August 2026 1
Slide 2: Forward Looking Statement
Forward Looking Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements and relate to or are based on estimates regarding market and industry data that Shoulder Innovations, Inc. (the "Company") prepared based on management's knowledge an
Slide 3: Transforming Shoulder Surgical Care
Transforming Shoulder Surgical Care Initial focus on the ~$2.8B global annual shoulder arthroplasty market1; U.S. market growing >10% annually2 $33.9M Well-positioned as shoulder surgical care market grows in outpatient / ASC Net Revenue settings (YTD 2026) Purpose-built, disruptive ecosystem to add
Slide 4: Experienced Team Redefining Shoulder Surgical Care
Experienced Team Redefining Shoulder Surgical Care Rob Ball Jeff Points Matt Ahearn Dave Blue Jon Osborne Chief Executive Officer Chief Financial Officer Chief Operating Officer Chief Customer Chief Commercial Officer Experience Officer Proven History of Successful Shoulder Innovation and Commercial
Slide 5: Shoulder Pain is Highly Prevalent with Quality-of-Life-Reducing Impacts
Shoulder Pain is Highly Prevalent with Quality-of-Life-Reducing Impacts Key Drivers of Shoulder Pain Shoulder Pain is Widespread Osteoarthritis 1 in 5 People 8+ Million over 65 suffer from annual physician visits shoulder pain in the U.S. related to shoulder Rheumatoid Arthritis conditions in the U.
Slide 6: Shoulder Arthroplasty is Our Initial Focus Within Shoulder Surgical Care
Shoulder Arthroplasty is Our Initial Focus Within Shoulder Surgical Care Established Surgical Procedures for Reducing Joint Pain and Restoring Shoulder Motion Osteoarthritis Osteoarthritis + Rotator Cuff Deficiency Anatomic Total Shoulder Arthroplasty (aTSA) Reverse Total Shoulder Arthroplasty (rTSA
Slide 7: Shoulder Arthroplasty is One of the Fastest Growing MedTech Segments
Shoulder Arthroplasty is One of the Fastest Growing MedTech Segments Large & Growing TAM ASC Will Capture Future Growth Forward Market Growth Rate (%) Total Joint Arthroplasty Example3 ~$2.8B (MM) 2.0 >10% 2 Global Annual Market1 1.5 OUS Market 6 51% ~7% ~ $1.0B 7 ~5% 1.0 15% 7 7 ~4% ~4% U.S.Shoulde
Slide 8: Significant Limitations of Current Shoulder Arthroplasty Products Provide a Compelling Opportunity
Significant Limitations of Current Shoulder Arthroplasty Products Provide a Compelling Opportunity Low Rates of Implant Survivorship 40% of Implants Subject to Revision Surgery1 Frequent Post-Operative Complications 15% of Subscapularis Tendons Fail Following aTSA2 Imprecise Implant Positioning As L
Slide 9: We Have Developed a Highly Differentiated Ecosystem to Improve Core Components of Shoulder Surgical Care
We Have Developed a Highly Differentiated Ecosystem to Improve Core Components of Shoulder Surgical Care ProVoyance Enabling Technology Platform Advanced Implant Systems Efficient Instrument System Surgeon-to-Surgeon Collaboration Specialized Support 9
Slide 10: The InSet Glenoid is the Foundation of Our Implant Systems
The InSet Glenoid is the Foundation of Our Implant Systems and Sets a New Standard for Fixation and Stability Traditional Implant, Sitting on Top of Bony Surface Implant on top of the bone InSet Glenoid, Sitting Within a Rim of Bone Complex articular Peripheral bone ledge is surface further reduces
Slide 11: Data Demonstrates Significant Clinical Benefits and Improved Patient Outcomes of InSet Glenoid
Data Demonstrates Significant Clinical Benefits and Improved Patient Outcomes of InSet Glenoid Key Clinical Factors InSet's Differentiation Pre-Operation Rotation Forward Flexion 87% Reduction2 In “Rocking Horse” Motion In constant pain and unable to Pain-free and enjoying better complete daily ac
Slide 12: InSet Glenoid Technology Leveraged Across a Full Range of Solutions for Both aTSA and rTSA
InSet Glenoid Technology Leveraged Across a Full Range of Solutions for Both aTSA and rTSA Procedures InSet aTSA System InSet rTSA System 12
Slide 13: Common Post-Operative aTSA Complications Require Surgical Conversion to rTSA
Common Post-Operative aTSA Complications Require Surgical Conversion to rTSA However, Traditional Implants are Not Designed for Replacement, Revision, or rTSA-Conversion Procedures Traditional Implants…. Post-Operative Complications Can Include… Overstuffing, shoulder dislocation, humeral fractures,
Slide 14: Frequency of Post-Operative aTSA Complications are Driving Significantly Higher rTSA Volumes
Frequency of Post-Operative Gradual Market Transition Towards aTSA Complications are Driving Inlay Reverse Arthroplasty Significantly Higher rTSA Volumes Evolution of Shoulder Arthroplasty Procedure Mix Onlay 100% Arthroplasty 80% 60% Reverse now 70%+ of procedures 40% Inlay 20% Arthroplasty 0% Tota
Slide 15: InSet Reverse System Provides Biomechanical Advantages
InSet Reverse System Provides Biomechanical Advantages Engineered to Provide Bone Sparing Implant Options to Achieve Desirable Range of Motion Biomechanics Biomechanical advantage: a more 41% “anatomic” reverse shoulder Traditional construct of rTSAs Have Limited Reverse Internal Rotation after Surg
Slide 16: InSet Stems Are Compatible Across a Full Range of Implant Systems
InSet Stems Are Compatible Across a Full Range of Implant Systems For Interchangeability Between aTSA and rTSA All InSet Stems are Compatible with Both …Making Revision / Conversion Surgeries Three InSet Stem Options aTSA & rTSA Humeral Heads… Straightforward Stemless aTSA InSet Humeral Head 70% of
Slide 17: Our Capital Efficient Technology Suite Reduces Complexity & Cost
Our Capital Efficient Technology Suite Reduces Complexity & Cost… Status Quo Significant Reduction Up to 9 surgery trays to complete a single procedure in Surgery Tray Usage ✓ Full SI product portfolio and all procedures supported by two instrument trays ✓ Fewer SKUs and trays reduce the implant foo
Slide 18: …and Supports a Broader Market Shift Towards ASC Setting
…and Supports a Broader Market Shift Towards ASC Setting Transition to thetoOutpatient Continued Transition the OutpatientSetting Setting ASCs as Site of Care Present Numerous Advantages Inpatient Outpatient ✓ ASC has emerged as a cost-efficient site of care delivery for shoulder arthroplasty <30% ~
Slide 19: ProVoyance Enabling Technology Platform
ProVoyance Enabling Technology Platform: A Core Engagement Center for Our Customers Pre-Operative Planning Micro-Robotic Integration Intra-Operative Execution • Hands-on, enhanced procedural planning performed by surgeons at the site of care • Next-generation platform currently in development, to de
Slide 20: Introducing InSet Neo: A Micro-Robotic Solution for Shoulder Arthroplasty
Introducing InSet Neo: A Micro-Robotic Solution for Shoulder Arthroplasty ✓ Fully compatible with next-gen ProVoyance platform, creating one integrated enabling technology suite Developing in Partnership With: ✓ New economic model with no capital burden – portable, case-by-case deployment that enabl
Slide 21: Integrated Commercial Approach Accelerates Adoption, Drives Deeper Relationships and Long-Term Retention
Integrated Commercial Approach Accelerates Adoption, Drives Deeper Relationships and Long-Term Retention Commercial Leadership: CEME: Distributor Management, Target Prospecting, ip C rsh Me ust Key Account Conversions, Utilization Forecasting, Performance Management e dic o ad al Management, Surgeon
Slide 22: Consistent Innovation & Robust Pipeline of Increasingly Differentiated Technologies
Consistent Innovation & Robust Pipeline of Increasingly Differentiated Technologies 2016 – 2025 Key Launches 1H 2026 2H 2026 2027 Full launches: Limited launches: FDA submissions: ✓ InSet 135RFX • InSet Clutch guide system • InSet Neo: Micro- robotic humeral stem system • Subscapularis tendon
Slide 23: History of Consistent Above-Market Revenue Growth
History of Trailing Twelve Months (TTM) Revenue Consistent ($ in USD millions) $60.1 Above-Market ~50% CAGR 1 $53.9 Revenue Growth $47.3 $41.6 $37.3 Q2 2026 Highlights: $34.6 • Revenue of $17.2M, 56% Y/Y $26.7 • 2,238 implant systems sold, ~50% Y/Y • Continued rapid increase in new surgeons • Gross
Slide 24: Multiple Drivers to Sustain Above-Market Growth
Multiple Drivers to Sustain Above-Market Growth Entry into Sports Medicine and Trauma Long-Term Above Entry into select Market Growth international ~$7.7K Current ASP4 markets New Indications will have higher ASPs Revision, Fracture, Metal Sensitivity Near-Term Above indications Market Growth ~1,800
Slide 25: Multiple Initiatives to Drive Profitability
Multiple Initiatives to Drive Profitability Attractive Gross Margin Profile Key Profitability Initiatives 79% 78% Manufacturing and 77% 77% ASP Supply Chain Cost- Down Initiatives R&D and SG&A Spend Salesforce Productivity Moderating as a Function of Revenue Modest Capex Improving Working Investment
Slide 26: Transforming Shoulder Surgical Care
Transforming Shoulder Surgical Care Initial focus on the ~$2.8B global annual shoulder arthroplasty market1; U.S. market growing 10% annually2 Well-positioned as shoulder surgical care market grows in outpatient / ASC settings Purpose-built, disruptive ecosystem to address existing limitations withi
Slide 27: Thank You
SHOULDER INNOVATIONS Thank You
Shoulder Innovations — Investor Presentation (August 2026) on 6ix